Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Proscia›
Analysis
AddedJan 26, 2023
UpdatedJul 16, 2026
Proscia

Proscia

A digital pathology platform advancing research and diagnostics towards a data-driven discipline.

HQ
Philadelphia, PA, US
Founded
2014
Loading
Overview
Analysis
Compare
Fundraising
Employees
Website
Relative Profitability
TEST

Contents

  1. 01Products & Services
  2. 02Competitive Strengths
  3. 03Competitive Risks
  4. 04Pricing Strategy
  1. 01Products & Services
  2. 02Competitive Strengths
  3. 03Competitive Risks
  4. 04Pricing Strategy

Product Overview

Proscia is a computational pathology company that develops software tools for use in pathology labs. The company's primary product is its flagship platform, Concentriq. This platform uses advanced algorithms and artificial intelligence (AI) to help pathologists process and analyze large volumes of digital pathology images quickly and accurately. The platform can be used by pathologists and other healthcare professionals to diagnose and treat a wide range of diseases and conditions.

Concentriq has several features that help to improve the accuracy and efficiency of pathology workflows. These features include:

Automated Image Analysis: The platform uses advanced algorithms and AI to automatically analyze pathology images, helping to identify abnormalities and other features that may be indicative of disease.

Data Management: Concentriq provides a centralized platform for storing and managing pathology data, making it easier for pathologists and other healthcare professionals to access and analyze data from a wide range of sources.

Collaboration Tools: The platform includes a range of collaboration tools that allow pathologists and other healthcare professionals to work together on pathology cases, share images and data, and provide feedback and support to one another.

Workflow Optimization: Concentriq is designed to optimize pathology workflows, helping to reduce the time and resources required to analyze pathology images and generate accurate diagnoses.

Integration with Existing Systems: The platform is designed to integrate with existing pathology systems, allowing healthcare professionals to easily incorporate digital pathology into their existing workflows.

Overall, Proscia's product provides a comprehensive digital pathology solution that helps to improve the accuracy, efficiency, and speed of pathology workflows. Its advanced algorithms and AI capabilities, combined with its collaborative features and workflow optimization tools, make it a valuable tool for pathologists and other healthcare professionals who need to diagnose and treat a wide range of diseases and conditions.

Competitive Advantages

Proscia's advantage relative to its competition lies in its advanced image analysis and AI capabilities, its ability to streamline pathology workflows, and its collaboration and data management features.

First, Proscia's image analysis and AI capabilities are among the most advanced in the digital pathology market. Its algorithms and machine learning models are designed to detect and analyze pathology images with high accuracy and speed, reducing the time and resources required to analyze and diagnose diseases. This can give pathologists and healthcare professionals the confidence they need to make accurate diagnoses and treatment decisions.

Second, Proscia's platform is designed to streamline pathology workflows, helping to reduce the time and resources required to process and analyze large volumes of pathology data. The platform's automated analysis and data management features can help to simplify and speed up pathology workflows, enabling pathologists and healthcare professionals to focus on delivering high-quality patient care.

Third, Proscia's collaboration and data management features are designed to help pathologists and healthcare professionals work together more effectively. The platform provides a centralized platform for storing and managing pathology data, making it easier for healthcare professionals to access and analyze data from a wide range of sources. The collaboration tools also enable pathologists and healthcare professionals to work together on pathology cases, share images and data, and provide feedback and support to one another.

Overall, Proscia's advanced image analysis and AI capabilities, workflow optimization features, and collaboration and data management tools provide a unique and valuable set of benefits to its customers, setting it apart from its competitors in the computational pathology market.

Competitive Disadvantages

One of Proscia's potential disadvantages relative to its competition is its focus on a cloud-based delivery model. While the cloud-based model provides several benefits, such as ease of deployment, scalability, and lower upfront costs, it may not be suitable for all healthcare organizations, particularly those with concerns around data privacy and security. These organizations may prefer to use on-premises digital pathology solutions that allow them to maintain complete control over their data and infrastructure.

Another potential competitive disadvantage for Proscia is its relatively smaller customer base compared to some of its larger competitors. While Proscia has experienced significant growth in recent years, it may face challenges in competing with larger, established players in the digital pathology market that have deeper pockets and more extensive customer bases.

Additionally, Proscia's AI and machine learning capabilities may require extensive training and customization to achieve optimal performance for each customer, which may be a disadvantage for smaller labs or healthcare organizations with limited resources or technical expertise.

Finally, Proscia's pricing may be seen as relatively higher compared to some of its competitors. While Proscia's advanced image analysis and AI capabilities, workflow optimization features, and collaboration and data management tools provide a unique set of benefits, some healthcare organizations may prefer lower-priced options that provide similar features and functionality.

Overall, while Proscia has several competitive advantages in the computational pathology market, it may face challenges in competing with larger, established players, as well as addressing concerns around data privacy and security, training and customization requirements, and pricing.

Pricing Strategy

Proscia's pricing strategy is based on a subscription model that offers its flagship platform, Concentriq, as a Software as a Service (SaaS) product. This means that customers pay a recurring subscription fee to access the platform and its features.

The company offers several pricing plans that are designed to meet the needs of different types of customers, such as small labs, medium-sized labs, and large healthcare organizations. Each pricing plan includes different features and functionality, with higher-tier plans offering more advanced features and greater customization options.

Proscia's pricing model is designed to be flexible and scalable, allowing customers to adjust their subscription plans as their needs change. The company also offers a range of professional services, such as training and support, that can be purchased separately to help customers maximize the value of the platform.

One of the benefits of Proscia's pricing model is that it allows customers to access the latest features and capabilities of the platform without having to make significant upfront investments in hardware or software. This can help to reduce the overall cost of ownership and make it easier for labs and healthcare organizations to adopt digital pathology technology.

Overall, Proscia's pricing model is competitive and flexible, and is designed to help customers of all sizes and types to access the benefits of its advanced digital pathology platform.